Shots:
- The P-III TULIP program involves two P-III trials (TULIP 1 & 2) assessing the efficacy & safety of anifrolumab (150mg/300mg, 300mg, q4w) vs PBO in (457 & 362) patients in ratio (1:2:2) & (1:1) with SLE resectively
- The new post-hoc analysis showed improvements in both skin rash & arthritis across three different disease measures, SLEDAI (13.5% & 8.2%), BILAG (15.5% & 11.8%) and 15.6% mCLASI for skin rash & 12.6% joint response for arthritis. TULIP-1 did not meet its 1EPs based on the SRI4 composite measure
- The application is under review by regulatory authorities in the US, EU, and Japan, with decisions anticipated in H2’21
Click here to read full press release/ article | Ref: AstraZeneca | Image: Mint
The post AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021 first appeared on PharmaShots.
